Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | CDKN2A |
Variant | over exp |
Impact List | none |
Protein Effect | no effect |
Gene Variant Descriptions | CDKN2A over exp indicates an over expression of the Cdkn2a protein. However, the mechanism causing the over expression is unspecified. |
Associated Drug Resistance | |
Category Variants Paths |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03838263 | Phase II | Nivolumab | Feasibility and Tolerance of Nivolumab Neoadjuvant Immunotherapy in High Risk HPV Driven Oropharynx Cancer (IMMUNEBOOST) | Active, not recruiting | FRA | 0 |
NCT04574583 | Phase Ib/II | Bintrafusp alfa + FPV-CV301 + MVA-BN-CV301 + SX-682 | Phase I/II Trial Investigating the Safety, Tolerability, Pharmacokinetics, Immune and Clinical Activity of SX-682 in Combination With BinTrafusp Alfa (M7824 or TGF-beta "Trap"/PD-L1) With CV301 TRICOM in Advanced Solid Tumors (STAT) | Completed | USA | 0 |
NCT03242382 | Phase II | Palbociclib | Trial of Palbociclib in Second Line of Advanced Sarcomas With CDK4 Overexpression. (PalboSarc) | Recruiting | ESP | 0 |